Log in to save to my catalogue

Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP...

Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2730319629

Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug

About this item

Full title

Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug

Publisher

Abingdon: Taylor & Francis

Journal title

Journal of enzyme inhibition and medicinal chemistry, 2023-01, Vol.38 (1), p.51-66

Language

English

Formats

Publication information

Publisher

Abingdon: Taylor & Francis

More information

Scope and Contents

Contents

ARS-interacting multifunctional proteins 2 (AIMP2) is known to be a powerful tumour suppressor. However, the target AIMP2-DX2, AIMP2-lacking exon 2, is often detected in many cancer patients and cells. The predominant approach for targeting AIMP-DX2 has been attempted via small molecule mediated inhibition, but due to the lack of satisfactory activ...

Alternative Titles

Full title

Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2730319629

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2730319629

Other Identifiers

ISSN

1475-6366

E-ISSN

1475-6374

DOI

10.1080/14756366.2022.2135510

How to access this item